CLINICAL PRACTICE GUIDELINES UPDATE: PART 2 (NAFLD & DIABETES; PHARMACOLOGIC GLYCEMIC MANAGEMENT OF TYPE 2 DIABETES IN ADULTS - CHAPTER & USER'S GUIDE; CKD & DIABETES) / MISE À JOUR DES LIGNES DIRECTRICES DE PRATIQUES CLINIQUES - DEUXIÈME PARTIE : STÉATOSE HÉPATIQUE NON-ALCOOLIQUE ET DIABÈTE; GESTION PHARMACOLOGIQUE DE LA GLYCÉMIE CHEZ LES ADULTES VIVANT AVEC LE DIABÈTE DE TYPE 2 - CHAPITRES ET GUIDE DE L'UTILISATEUR; INSUFFISANCE RÉNALE CHRONIQUE ET DIABÈTE (DC-024)

Saturday, October 28, 2023

16:30 – 17:30 EST

Location: Palais, 517BC

Presenter(s)

Sonia Butalia, MD, FRCPC, MSc (she/her/hers)

Associate Professor of Medicine and Community Health Sciences Medical Director of Implementation Science, Physician Learning Program University of Calgary
University of Calgary
University of Calgary
James W. Kim, MBBCh, PgDip, MScCH(HPTE) (he/him/his)

Clinical Assistant Professor
University of Calgary
University of Calgary
Giada Sebastiani, MD (she/her/hers)

Hepatologist
McGill University Health Centre
McGill University

PDF
Baiju R. Shah, MD PhD

Head
Division of Endocrinology, Sunnybrook Health Sciences Centre
University of Toronto
Sheldon Tobe, MD, MScCH, FRCPC, FACP, FAHA

Physician
Sunnybrook Health Sciences Centre and Northern Ontario School of Medicine
Sunnybrook Health Sciences Centre and Northern Ontario School of Medicine

Disclosure(s):

Harpreet S. Bajaj, MD, MPH, ECNU, FACE: Amgen: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Anji: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); AstraZeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Boehringer Ingelheim: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Eli Lilly: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Kowa: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novo Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Sonia Butalia, MD, FRCPC, MSc: No financial relationships to disclose

James W. Kim, MBBCh, PgDip, MScCH(HPTE): Abbott: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Abbvie: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Academy for Continued Advancement in Healthcare Education: Speaker/Honoraria (Ongoing); AstraZeneca: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing); Boehringer-Ingelheim: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); CCRN: Speaker/Honoraria (Ongoing); CPD Network: Speaker/Honoraria (Ongoing); Eisai: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Embecta: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GSK: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); HIT Global: Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Liv Agency: Speaker/Honoraria (Ongoing); MDBriefcase: Speaker/Honoraria (Ongoing); Miravo Pharm: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Moderna: Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Otsuka: Speaker/Honoraria (Ongoing); Pfizer: Speaker/Honoraria (Ongoing); PPME: Speaker/Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Takeda: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Teva: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Giada Sebastiani, MD: No financial relationships to disclose

Baiju R. Shah, MD PhD: No financial relationships to disclose

Sheldon Tobe, MD, MScCH, FRCPC, FACP, FAHA: CHEP+: Speaker/Honoraria (Ongoing); Janssen: Speaker/Honoraria (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

NAFLD: Describe the current knowledge on epidemiology, diagnosis, and treatment of NAFLD/NASH in individuals living with diabetes, and explain clinical guidance on assessment and management
Diabetes and Chronic Kidney Disease: Describe the updated treatment and management of kidney disease for people living with diabetes
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: Explain the recent updates to the recommendations for pharmacological management of type 2 diabetes in adults